WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Study sponsor: Sellas Life Sciences Group
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-09-30Actual
Enrollment · participants22Actual
Source updated2024-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.